You are viewing the site in preview mode

Skip to main content

Advertisement

Table 4 Comparison basic clinical characteristics and outcomes of patient not treated by MTX or treated by MTX

From: Management of Caesarean scar pregnancy with or without methotrexate before curettage: human chorionic gonadotropin trends and patient outcomes

  Mean ± SD/Rate P value
Not treated by MTX (n = 47) treated by MTX (n = 60)  
Age (years) 32.04 ± 6.283 31.85 ± 5.544 0.867
Gestational age at diagnosis (days) 52.68 ± 11.664 49.37 ± 10.096 0.119
Fetal heart beat positive, n (%) 15(31.9%) 26(43.3%) 0.299
B:After MTX treatment or before curettage (mIU/ml) 31,163.48 ± 28,626.86 52,841.27 ± 41,148.83 0.003
C:Three days after curettage (mIU/ml) 2838.68 ± 3.10 4161.63 ± 4.52 0.090
C/B 0.085 ± 0.04 0.082 ± 0.05 0.856
Intraoperative blood loss (ml) 39.83 ± 16.96 52.37 ± 40.2 0.051
Pregnancy tissue retained, n (%) 1(2.1%) 3(5.0%) 0.437
Hospital stay (days) 7.00 ± 2.29 10.58 ± 3.35 <0.001